Dr. Cipriani is a surgical pathologist with a clinical subspecialty focus in Head & Neck, Thyroid, and Bone & Soft Tissue Pathology. Her diagnostic and research interests include neoplastic diseases of the thyroid gland, salivary glands, and upper aerodigestive tract. She also has an interest in Anatomic Pathologic Informatics, including web design, digital imaging, and virtual slides.
Co-Director of Surgical Pathology, The University of Chicago
Director of Anatomic Pathology Informatics, The University of Chicago
Treasurer, North American Society of Head & Neck Pathology
Massachusetts General Hospital
Boston, MA
Fellowship - Head & Neck and Bone & Soft Tissue Pathology
2013
The University of Chicago
Chicago, IL
Residency - Anatomic & Clinical Pathology
2012
The University of Chicago Pritzker School of Medicine
Chicago, IL
MD - Medicine
2008
The University of Illinois at Chicago
Chicago, IL
MS - Medical Illustration / Biomedical Visualization
2004
The University of Chicago
Chicago, IL
AB - Biological Sciences & Visual Arts
2002
Neoadjuvant Nivolumab Plus Chemotherapy Followed by Response-Stratified Chemoradiation Therapy in HPV-Negative Head and Neck Cancer: The DEPEND Phase 2 Nonrandomized Clinical Trial.
Neoadjuvant Nivolumab Plus Chemotherapy Followed by Response-Stratified Chemoradiation Therapy in HPV-Negative Head and Neck Cancer: The DEPEND Phase 2 Nonrandomized Clinical Trial. JAMA Oncol. 2025 May 01; 11(5):492-501.
PMID: 40048190
Prevalence and Clinical Impact of BRAF p.V600E Mutation in Papillary Thyroid Carcinoma.
Prevalence and Clinical Impact of BRAF p.V600E Mutation in Papillary Thyroid Carcinoma. Endocr Pathol. 2025 Apr 16; 36(1):13.
PMID: 40237893
Analysis of AI foundation model features decodes the histopathologic landscape of HPV-positive head and neck squamous cell carcinomas.
Analysis of AI foundation model features decodes the histopathologic landscape of HPV-positive head and neck squamous cell carcinomas. Oral Oncol. 2025 Apr; 163:107207.
PMID: 40043423
DEK :: AFF2 Fusion Sinonasal and Skull Base Nonkeratinizing Squamous Cell Carcinoma : A Clinical Outcome Study Compared With Conventional Sinonasal Squamous Cell Carcinoma.
DEK :: AFF2 Fusion Sinonasal and Skull Base Nonkeratinizing Squamous Cell Carcinoma : A Clinical Outcome Study Compared With Conventional Sinonasal Squamous Cell Carcinoma. Am J Surg Pathol. 2025 Feb 01; 49(2):130-137.
PMID: 39719672
Seven years of Non-invasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features (NIFTP): Rate of Acceptance and Variation of Diagnostic Approaches Across Different Continents.
Seven years of Non-invasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features (NIFTP): Rate of Acceptance and Variation of Diagnostic Approaches Across Different Continents. J Clin Endocrinol Metab. 2024 Dec 18; 110(1):166-175.
PMID: 38874075
Artificial intelligence-based morphologic classification and molecular characterization of neuroblastic tumors from digital histopathology.
Artificial intelligence-based morphologic classification and molecular characterization of neuroblastic tumors from digital histopathology. NPJ Precis Oncol. 2024 Nov 08; 8(1):255.
PMID: 39511421
Adenoid Cystic Carcinoma with Sebaceous Differentiation and MYB::NFIB Fusion Arising in the External Auditory Canal.
Adenoid Cystic Carcinoma with Sebaceous Differentiation and MYB::NFIB Fusion Arising in the External Auditory Canal. Head Neck Pathol. 2024 Sep 23; 18(1):85.
PMID: 39312083
Update of newly-recognized salivary gland neoplasms: molecular and immunohistochemical findings and clinical importance.
Update of newly-recognized salivary gland neoplasms: molecular and immunohistochemical findings and clinical importance. Histopathology. 2025 Jan; 86(2):183-198.
PMID: 39108216
Neoadjuvant Nivolumab Plus Chemotherapy Followed By Response-Adaptive Therapy for HPV+ Oropharyngeal Cancer: OPTIMA II Phase 2 Open-Label Nonrandomized Controlled Trial.
Neoadjuvant Nivolumab Plus Chemotherapy Followed By Response-Adaptive Therapy for HPV+ Oropharyngeal Cancer: OPTIMA II Phase 2 Open-Label Nonrandomized Controlled Trial. JAMA Oncol. 2024 Jul 01; 10(7):923-931.
PMID: 38842838
Columnar Cell Thyroid Carcinoma: A Heterogeneous Entity Demonstrating Overlap Between Papillary Thyroid Carcinoma and Follicular Neoplasms.
Columnar Cell Thyroid Carcinoma: A Heterogeneous Entity Demonstrating Overlap Between Papillary Thyroid Carcinoma and Follicular Neoplasms. Head Neck Pathol. 2024 May 10; 18(1):39.
PMID: 38727854